Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Topics: Peripheral IVL, IVL Technology, Peripheral Conferences, Peripheral Clinical Data
At AMP 2022, Dr. Peter Soukas presented the largest set of real-world data on Shockwave IVL in CLI patients. These data include results from patient groups historically not included in other PAD studies, such as Rutherford 6 and dialysis patients, and patients with single or absent vessel run-off. These data show the significant reduction of stenosis post-IVL in these patients, the minimal complications and the consistent results across multiple vessel beds. In this presentation Dr. Soukas shares why these data are important for physicians who treat CLI, and how his calcium modification algorithm has changed over time with IVL.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data, Shockwave M5 & Shockwave M5+
Calcified lesions in CLTI patients pose a number of hurdles for endovascular therapy including acute and sub-acute recoil, flow-limiting dissections and distal embolization. In this presentation from Charing Cross 2022 Dr. Thulasidasan shares how Shockwave IVL has improved his treatment for CLTI patients with low complications and increased durability. Dr. Thulasidasan walks through case examples with IVL in CLTI patients and states how the data supporting IVL backs up what he’s seeing in practice.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data
In this three-episode tutorial series, Dr Stefano Fazzini and Dr Michel Bosiers provide an excellent overview on how IVL removes the barriers of calcified hostile access and expands treatment boundaries in EVAR and TEVAR procedures by changing vessel compliance, facilitating luminal gain and significantly reducing complications.
Topics: Peripheral IVL, Peripheral Clinical Data
It’s no exaggeration that calcium represents the Achilles heel of endovascular treatment. As the patient population continues to evolve in complexity we need solutions that can treat severe calcified disease in an efficacious, safe and durable way. Listen as Dr Konstantinos Stavroulakis shares the outcomes of his recent publication of Intravascular Lithotripsy (IVL) and DCB in severely calcified femoropopliteal lesions followed out to 12 months and understand why he believes IVL is a game changer in the treatment of complex real world patients.
Topics: Peripheral IVL, Peripheral Clinical Data
The presence of calcium can pose significant challenges in achieving optimal procedural outcomes in PAD treatment and can pose as a barrier to the delivery of large bore access devices. Shockwave IVL is shifting the paradigm in the way physicians approach calcium by simplifying procedures in an efficacious and safe manner. Now the next generation of peripheral IVL technology is here: Shockwave M5+! The Shockwave M5+ extends treatment options with the introduction of its new features; faster pulsing, an extended working length and expanded size matrix.
Topics: Peripheral IVL, Peripheral Clinical Data, Shockwave M5 & Shockwave M5+
Alternative access strategies in TAVI are prone to higher complication rates when compared to transfemoral access. This leads to the question; should physicians tackle difficult transfemoral over alternative access?
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data
Great news! The Centers for Medicare and Medicaid Services (CMS) has increased payment for peripheral IVL procedures. The increases apply to procedures performed in anatomical locations above the knee in a hospital outpatient setting. The changes go into effect on January 1, 2022.
Topics: Peripheral IVL, Peripheral Clinical Data, Reimbursement
Transfemoral access represents the gold standard for TAVI, with TF access showing a significant reduction in complications and mortality in comparison to alternative access strategies, which add additional complexity and risk to the procedure. Despite the wide acceptance that the transfemoral route provides the safest access for patients, the approach can be hindered by calcified iliac arteries inhibiting delivery of large bore devices by restricting the luminal diameter and reducing vessel compliance. If calcium is not treated adequately prior to TAVI delivery, this can lead to complications such as flow limiting dissection, vessel rupture and unsuccessful delivery of the implant.
Topics: Peripheral IVL, Peripheral Clinical Data
On Thursday, November 18, join us and six IVL experts at VEITH 2021 to hear how Intravascular Lithotripsy (IVL) works across multiple vessel beds.
Topics: Peripheral IVL, Peripheral Conferences, Peripheral Clinical Data
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
